ImmuCell Corporation (ICCC)

Market Cap	64.01M +50.3%
Revenue (ttm)	27.64M +4.3%
Net Income	-1.04M
EPS	-0.12
Shares Out	9.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,140
Open	7.34
Previous Close	7.19
Day's Range	7.04 - 7.34
52-Week Range	4.52 - 7.60
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About ICCC

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Masti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 1987
• Employees: 84
• Stock Exchange: NASDAQ
• Ticker Symbol: ICCC
• Website: https://immucell.com

Financial Performance

In 2025, ImmuCell's revenue was $27.64 million, an increase of 4.34% compared to the previous year's $26.49 million. Losses were -$1.04 million, -51.78% less than in 2024.